Scarica l'app Stockscreener
37.74
1.56%
0.58
Dopo l'orario di chiusura:
37.74
Collegium Pharmaceutical Inc Borsa (COLL) Ultime notizie
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by HC Wainwright to "Strong-Buy" Rating - MarketBeat
Is Collegium Pharmaceutical's (COLL) Revenue Guidance and Buyback Balancing Short-Term Results With Long-Term Value? - simplywall.st
Collegium pharma EVP Dreyer sells $184,880 in stock - Investing.com
Collegium pharma EVP Dreyer sells $184,880 in stock By Investing.com - Investing.com Australia
Collegium Pharmaceutical EVP Scott Dreyer Sells 4,861 Shares, Buys 4,861 at $38.03/Share. - AInvest
Have Collegium Pharmaceutical Insiders Been Selling Stock? - 富途牛牛
Published on: 2025-08-16 02:26:13 - thegnnews.com
We Think You Can Look Beyond Collegium Pharmaceutical's (NASDAQ:COLL) Lackluster Earnings - Yahoo Finance
How Collegium Pharmaceutical Inc. stock performs during market volatility2025 Trading Recap & Safe Capital Growth Plans - beatles.ru
RSI Suggests Rebound May Be Near in Collegium Pharmaceutical Inc.Weekly Trade Summary & Daily Profit Maximizing Tips - sundaytimes.kr
Collegium Pharmaceutical Inc. Nearing Breakout Level After BounceJuly 2025 Gainers & Safe Entry Trade Reports - beatles.ru
Technical analysis overview for Collegium Pharmaceutical Inc. stockQuarterly Earnings Report & Technical Pattern Recognition Alerts - Newser
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to “Strong-Buy” at HC Wainwright - Defense World
Can Collegium Pharmaceutical Inc. recover in the next quarterJuly 2025 Reactions & Safe Capital Growth Plans - Newser
Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics - MSN
The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call - Yahoo Finance
Collegium Pharmaceutical Inc. Bounces Off Moving Average SupportQuarterly Trade Summary & Long Hold Capital Preservation Tips - sundaytimes.kr
IBD Rating Upgrades: Collegium Pharmaceutical Flashes Improved Relative Price Strength - MSN
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by Wall Street Zen to "Strong-Buy" Rating - MarketBeat
HC Wainwright Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to Strong-Buy - Defense World
3 Profitable Stocks We Think Twice About - Yahoo Finance
COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure - Yahoo Finance
Collegium Pharmaceutical Shows Market Leadership With Jump To 81 RS Rating - Investor's Business Daily
Collegium Pharmaceutical Earns Membership In 95-Plus Composite Rating Club - MSN
H.C. Wainwright assumes coverage on Collegium Pharmaceutical stock with Buy rating - Investing.com Canada
Collegium Pharmaceutical (COLL) Is Up 16.2% After Raising 2025 Revenue Guidance on Strong Q2 Results - simplywall.st
Sector ETF performance correlation with Collegium Pharmaceutical Inc.Smart Risk Strategy with Entry Optimization - Newser
Collegium Pharmaceutical's Q2 2025: Key Contradictions on Jornay PM Sales Estimates and Pain Portfolio Competition - AInvest
Can swing trading help recover from Collegium Pharmaceutical Inc. lossesPortfolio Positioning Strategy With Timing - Newser
Collegium Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Collegium Pharmaceutical Inc Q2 2025 Earnings: Revenue Exceeds Estimates at $188 Million - AInvest
Collegium Pharmaceutical Inc. Attempts Reversal From Key SupportWeekly Stock Opportunity Radar Scanner Activated - beatles.ru
Why Collegium Pharmaceutical (COLL) Rose 10.3% After Raising 2025 Revenue Guidance Despite Lower Earnings - simplywall.st
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2025 Earnings Call Transcript - Insider Monkey
Collegium Pharmaceutical: Q2 Earnings Snapshot - Greenwich Time
Collegium Pharmaceutical Inc (COLL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Collegium Pharmaceutical Reports Strong Q2 2025 Results - TipRanks
Collegium Pharmaceuticals Reports Strong Earnings and Growth - TipRanks
Collegium Pharmaceutical shares rise 1.70% after-hours following Q2 earnings beat. - AInvest
Truist Securities raises Collegium Pharmaceutical stock price target to $45 By Investing.com - Investing.com Australia
Collegium Pharmaceutical’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating - TipRanks
Needham Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $46 - 富途牛牛
Collegium Pharmaceutical Exceeds Q2 Expectations, Reporting 29.4% YoY Revenue Growth and a 10.2% Stock Jump. - AInvest
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2% - Yahoo Finance
Collegium raises 2025 revenue guidance to $760M as Jornay PM growth accelerates - MSN
Collegium Pharmaceutical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Collegium Pharmaceutical Q2 2025 slides: Revenue surges 29%, guidance raised - Investing.com
Collegium Pharmaceutical Q2 2025 slides: Revenue surges 29%, guidance raised By Investing.com - Investing.com South Africa
Transcript : Collegium Pharmaceutical, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates - sharewise.com
2.80%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):